Aberrant expression of WWOX protein in epithelial ovarian cancer: A clinicopathologic and immunohistochemical study

International Journal of Gynecological Pathology

Volumn 31, Issue 2, 2012, Pages 125-132

  Lan, Chao ^a   Chenggang, Wang ^a   Yulan, Bu ^a   Xiaohui, Deng ^a   Junhui, Zhen ^b   Xiao, Wang ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

3AO cell; Epithelial ovarian carcinoma; SKOV3 cell; WWOX

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; OXIDOREDUCTASE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER TISSUE; CARCINOMA CELL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OXIDOREDUCTASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84857186169     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3182297fd2     Document Type: Article

References (28)

1. Wang X, Chao L, Jin G, et al. Association between CpG islands methylation of the WWOX gene and its expression in breast cancers. Tumor Biol 2009;30:8-14.
2. Bednark AK, Laflin KJ, Daniel RL, et al. WWOX, a novel domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-5. (Pubitemid 30225175)
3. Nunez MI, Ludes-Meyers J, Abba MC, et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast cancer Res Treat 2005;89:99-105. (Pubitemid 40249042)
4. Nunez MI, Rosen DG, Ludes-Meyers JH, et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 2005;5:64.
5. Gourley C, Paige AJ, Taylor KJ, et al. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol 2005;26:1681-9.
6. Gourley C, Paige AJ, Taylor KJ, et al. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res 2009;69:4835-42.
7. Iliopoulos D, Guler G, Han SY, et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005;24:1625-33. (Pubitemid 40396092)
8. Wei SH, Balch C, Paik HH, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006;12:2788-94.
9. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37. (Pubitemid 33674041)
10. Scully RE, Sobin LH, Serov SF. Histological typing of ovarian tumours. In: World Health Organization. International Histological Classification of Tumours. Berlin: Springer 1999.
11. Greene FI, Page DI, Fleming ID, eds. AJCC Cancer Staging Manual. 6th ed. New York, Springer; 2002.
12. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15. (Pubitemid 30010638)
13. Guler G, Uner A, Guler N, et al. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 2005;55:471-8. (Pubitemid 41097847)
14. Middleton LP, Price KM, Puig P, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med 2009;133:775-80.
15. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
16. Crijns AP, Duiker EW, De Jong S, et al. Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. Int J Gynecol Cancer 2006;16:152-65.
17. Guler G, Ulner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004;100:1605-14. (Pubitemid 38456335)
18. Guler G, Iliopoulos D, Guler N, et al. Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res 2007;13:6115-21. (Pubitemid 350075070)
19. Verri E, Guglielmini P, Puntoni M, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Oncology 2005;68:154-61. (Pubitemid 41158970)
20. Mayr D, Kanitz V, Amann G, et al. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 2006;48:149-56.
21. de Graeff P, Crijns AP, Ten Hoor KA, et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 2008;99:341-9.
22. Tuefferd M, Couturier J, Penault-Llorca F, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2007;2:e1138.
23. Hogdall EV, Christensen L, Kjaer SK, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003;98:66-73. (Pubitemid 36741127)
24. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90. (Pubitemid 46606157)
25. Vermeij J, Teugels1 E, Bourgain C, et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008;8:3.
26. Sasaki N, Kudoh K, Kita T, et al. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma. J Obstet Gynaecol Res 2007;33:17-23. (Pubitemid 46025389)
27. Qin HR, Iliopoulos D, Nakamura T, et al. Wwox suppresses prostate cancer cell growth through modulation of ErbB2- mediated androgen receptor signaling. Mol Cancer Res 2007;5:957-65. (Pubitemid 47416672)
28. Guler G, Huebner K, Himmetoglu C, et al. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2 gamma expression levels correlate with basal phenotype in breast cancer. Cancer 2009;115:899-908.